Cigna genetic testing coverage update — Prior Auth

Coverage Criteria

Carrier testing for familial disease

Preconception or prenatal carrier testing for familial disease is considered medically necessary when ANY of the following are met:

Familial carrier testing criteria: There is an identified pathogenic or likely pathogenic variant in a blood relative; OR the individual's reproductive partner is a known carrier of a pathogenic or likely pathogenic variant for a recessively inherited condition; OR a genetic diagnosis has been confirmed in an affected relative AND the affected relative has not had genetic testing and is unavailable for testing.

Fragile X (FMR1) testing

Fragile X testing for individuals assigned female at birth is medically necessary when EITHER is present:

Fragile X indications: Family history of unexplained intellectual disability, developmental delay, or autism in a blood relative; OR personal or family history of premature ovarian insufficiency.

Specific gene testing (SMA, CF, hemoglobinopathies)

Specific single‑gene carrier testing is considered medically necessary when testing has not been previously performed and the individual has the capacity and intention to reproduce:

SMA: SMN1 gene variant analysis (CPT 81329) for spinal muscular atrophy when testing has not previously been performed.

Cystic fibrosis: Targeted CFTR variant analysis (CPT 81220) per ACMG guidance when testing has not previously been performed.

Hemoglobinopathies: Targeted testing for thalassemias and sickle cell disease (CPT 81257, 81361) when testing has not previously been performed.

Ethnicity‑based carrier screening

Ethnicity‑based carrier testing is considered medically necessary for prospective biologic parents of the specified ancestry when performed as a targeted single-gene analysis or targeted panel:

Ashkenazi Jewish panel: Single gene analysis or targeted panel (CPT 81412) for variants found in an individual of Ashkenazi Jewish descent is medically necessary.

Preimplantation genetic testing (PGT‑M, PGT‑SR)

Preimplantation genetic testing (PGT‑M, PGT‑SR) is covered when ALL of the following are met:

PGT criteria: The genetic condition is associated with severe disability or has a lethal natural history; AND the proposed test is medically necessary for the diagnosis/indication with sufficient evidence to demonstrate improved health outcomes; AND the results will impact clinical decision‑making; AND any of: both biologic parents are carriers of an autosomal recessive disorder; one biologic parent is a known carrier of an autosomal dominant or X‑linked disorder; one biologic parent is a translocation carrier.

Sequencing‑based NIPT (trisomy 13/18/21)

Sequencing‑based NIPT for common trisomies is covered when ALL of the following are met:

NIPT trisomy screening: Sequencing‑based NIPT (CPT 81420, 81507, 0327U) for fetal trisomy 13, 18, and 21 is medically necessary in a viable singleton or twin gestation ≥10 weeks gestation when testing has not already been performed.gestation >= 10 weeks

Positive screening results require confirmatory diagnostic testing (CVS or amniocentesis); counseling about 'no-call' results and limitations is required.

Invasive prenatal testing

Invasive prenatal testing of a fetus for a familial variant is medically necessary when ANY of the following apply:

Parental carrier scenarios: Mother is carrier of an X‑linked condition; OR both biologic parents are carriers of an autosomal recessive disorder OR the mother is a known carrier of an autosomal recessive disorder and the father's status is unknown/unavailable; OR one parent is carrier of an autosomal dominant disorder.

Other prenatal indications: Prenatal testing is medically necessary when abnormal ultrasound findings are identified; OR for prenatal reproductive evaluation when a woman is undergoing invasive prenatal genetic testing, in cases of intrauterine fetal loss ≥20 weeks or stillbirth, or intrauterine fetal loss with a documented structural anomaly at any gestational age.

Recurrent pregnancy loss testing

Recurrent pregnancy loss genetic evaluation is addressed as follows:

Medically necessary tests for recurrent loss: Peripheral-blood karyotyping of biologic parents; AND karyotyping or chromosomal microarray (CGH) of products of conception at the time of the second loss.

Tests considered not medically necessary: Molecular testing for highly skewed X‑inactivation and molecular cytogenetic testing using CGH on parental blood are considered not medically necessary; MTHFR polymorphism testing is not covered; single gene mutation analyses for recurrent pregnancy loss (e.g., F7 R353Q, F13B V34L, PAI‑1) are not supported.

Infertility‑related genetic testing

Genetic testing in evaluation of infertility is medically necessary when performed solely to establish etiology and specific criteria are met:

Infertility genetic testing: CFTR testing in males with congenital bilateral absence of vas deferens or azoospermia/severe oligospermia with palpable vas deferens; Y‑chromosome microdeletion testing in males with nonobstructive azoospermia or severe oligospermia; sperm penetration assay (hamster penetration test, CPT 89329) for men with male factor infertility who are considering IVF/ICSI.

NIPT for Trisomies 13, 18, 21

Covered when ALL of the following are met

NIPT_trisomy_coverage: Sequencing-based NIPT (cfDNA) is clinically supported for detection of fetal trisomy 13, 18, and 21 in a woman with a viable singleton pregnancy at ≥10 weeks gestation; positive screening results require confirmatory diagnostic testing (CVS or amniocentesis).gestation >= 10 weeks

High sensitivity and specificity reported; counseling about 'no-call' results and need for confirmatory testing is required.

Preimplantation Genetic Testing (PGT/PGD)

Covered when ANY of the following genetic risk scenarios are present and results will impact reproductive decision-making:

PGT_indications: Reproductive partners are carriers of a known single-gene autosomal recessive disorder; OR one partner is a known carrier of an autosomal dominant or X-linked heritable disorder; OR testing is being performed for severe, childhood-onset or lethal disorders where results will impact embryo selection.

PGT for nonmedical gender selection, nonmedical traits, PGT-P (polygenic risk), and testing solely to identify carrier status or for donor matching is not supported.

Germline Carrier Testing

Covered in targeted/family-history–driven contexts but not supported as broad, expanded pan-ethnic population screening without established gene selection criteria:

Carrier_testing_targeted: Targeted mutation analysis for conditions with known common mutations (e.g., CFTR targeted panel per ACMG, targeted HBB/HBA testing for thalassemia and sickle cell) is supported; very large expanded carrier panels lacking standard gene-selection criteria are not supported for general population screening.

Use a stepwise testing approach where sequencing or deletion/duplication studies are reserved for negative targeted results or when clinically indicated.

Invasive Prenatal Diagnostic Testing

Covered when ALL of the following apply

Invasive_prenatal_testing: Diagnostic invasive testing (CVS/amniocentesis) and prenatal chromosomal microarray (CGH/CMA) are supported when results will influence clinical management such as abnormal ultrasound, advanced maternal age, abnormal serum screening, positive family history, or when undergoing invasive prenatal testing for other indications.

Microarray demonstrates improved detection of clinically significant abnormalities versus karyotype in prenatal samples.

Prenatal invasive testing — CMA

Covered when ALL of the following are met (prenatal invasive testing context):

CMA for fetal structural anomalies: Fetus with one or more major structural abnormalities on ultrasound who is undergoing invasive prenatal diagnosis should have chromosomal microarray analysis; CMA replaces the need for fetal karyotype.

ACOG/SMFM recommendation.

Prenatal invasive testing — structurally normal fetus

Alternative/acceptable options when fetus is structurally normal:

Karyotype or CMA for structurally normal fetus: In patients with a structurally normal fetus undergoing invasive prenatal diagnostic testing, either fetal karyotyping or chromosomal microarray analysis can be performed.

ACOG/SMFM guidance.

Recurrent pregnancy loss

Recurrent pregnancy loss testing stance:

Karyotyping for recurrent pregnancy loss: Professional society consensus supports karyotyping of peripheral blood and products of conception in cases of two or more pregnancy losses; molecular cytogenetic testing is supported when karyotyping of products of conception is not possible due to lack of tissue or poor culture growth.

Society consensus.

CMA utility in recurrent pregnancy loss: Evidence for microarray analysis (CMA/CGH/SNP) utility in recurrent pregnancy loss is limited; systematic reviews report higher detection versus karyotype but overall prospective data are insufficient to establish clinical utility and impact on management.

Single-gene and thrombophilia testing

Single-gene and thrombophilia testing in recurrent pregnancy loss:

Single gene testing not indicated: Single gene mutation analysis is not indicated in the routine work-up of recurrent pregnancy loss due to insufficient evidence of clinical usefulness and lack of professional society support.

Specific coagulation gene tests not supported: Testing for certain gene variants (e.g., F7 R353Q, F13B V34L, PAI-1) lacks evidence that results improve health outcomes and is not supported.

Infertility evaluation

Infertility-related genetic testing:

Male infertility testing: Genetic testing is indicated when clinically relevant causes are suspected: targeted CFTR mutation analysis for men with congenital bilateral absence of the vas deferens; karyotyping and Y-chromosome microdeletion testing in males with nonobstructive azoospermia or severe oligospermia; sperm DNA integrity testing has not established clinical utility and is not recommended for routine use.

AUA/ASRM guidance.

Carrier screening

Carrier screening recommendations:

Offer carrier screening: ACMG and ACOG recommend offering carrier screening (including cystic fibrosis and spinal muscular atrophy) to all patients planning pregnancy or who are pregnant; ACMG recommends tier-three expanded carrier screening to promote equity across populations.

Carrier screening specifics: Carrier screening for conditions such as SMA, CF, fragile X, hemoglobinopathies, and Ashkenazi Jewish panel conditions should follow specialty guidance for whom to screen, when to offer partner testing, and genetic counseling.

NIPS / cfDNA

Noninvasive prenatal screening (NIPS/cfDNA) stance:

NIPS is screening only: Cell-free DNA screening is the most sensitive and specific screening test for common fetal aneuploidies but is not diagnostic; positive results should be confirmed with diagnostic testing; NIPS does not screen for single-gene mutations or open neural tube defects.

NIPS limitations: NIPS performance may be limited in multifetal gestations, vanishing twin situations, low fetal fraction, and for rare conditions where PPV is low; routine cfDNA screening for microdeletions is not recommended.

Medically Necessary Tests

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

General gene/test coverage: Specific single-gene and panel tests (numerous CPT codes listed) are considered medically necessary when the applicable clinical criteria in the policy are met.

See individual code entries for examples (e.g., CFTR, SMN1, HBB, HBA1/HBA2, FMR1).

Not Covered / Not Medically Necessary

Not covered or considered not medically necessary when used for the listed indications:

Excluded tests: Specific expanded carrier panels and certain noninvasive prenatal single-gene cfDNA tests (e.g., 81443, 0400U, 0489U) are Not Covered; certain variant reports (F7 R353Q, F13B V34L) and APOE and X-inactivation testing for recurrent pregnancy loss are Considered Not Medically Necessary.

Claims for these codes/uses may be denied.

Medically Necessary when applicable policy criteria are met

Covered when ALL of the following are met per applicable policy statements:

General requirement: The test is being used in a clinical scenario that meets the specific applicable policy statements referenced elsewhere in the document.

Applies to multiple listed CPT/HCPCS/U-codes (see coding groups).

Not Medically Necessary specific uses

Specific NMN uses: Reporting F7 R353Q or F13B V34L variants for recurrent pregnancy loss using 81400; reporting APOE common variants using 81401; molecular testing for highly skewed X-inactivation patterns for recurrent pregnancy loss (81401).

These uses are explicitly labeled Considered Not Medically Necessary.

Not Covered / Not Reimbursable

Explicitly not covered tests: MTHFR common variant testing (81291); whole genome sequence U-codes 0335U and 0336U; APOE epsilon 4 testing (S3852) are Not Covered or Reimbursable.

Prenatal microdeletion/microarray testing — medical necessity

Covered when ALL of the following are met:

Primary condition

Applicable diagnoses: An applicable maternal/fetal diagnosis code from the listed O34, O35, O36 ranges is documented (see ICD-10 list in the policy).

Exclusion: Not medically necessary when used to report not covered or reimbursable microdeletion testing.

Reporting excluded microdeletion testing may lead to noncoverage.

Covered when policy clinical criteria are met

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

General requirement: Testing codes listed as 'Considered Medically Necessary when criteria in the applicable policy statements listed above are met' require that the specific clinical criteria in the relevant policy sections are satisfied.

Applies to listed ICD-10 codes for pregnancy/fetal conditions and to listed CPT codes when clinical criteria are met.

Not Medically Necessary

Specific tests and uses considered not medically necessary:

Examples of NMN usage: 81229 (cytogenomic microarray) is Considered Not Medically Necessary when used to report reproductive genetic testing for recurrent pregnancy loss or preimplantation genetic screening for common aneuploidy; 81400 is Considered Not Medically Necessary when used to report PAI‑1 or certain thrombophilia-related variant testing in recurrent pregnancy loss.

Not Covered / Not Reimbursable

Tests explicitly listed as not covered or reimbursable:

Examples of Not Covered tests: 81422 and 0341U (fetal microdeletion and fetal aneuploidy sequencing from products of conception) are Not Covered or Reimbursable.

MTHFR and sperm DNA integrity: 81291 (MTHFR) and 88182 (flow cytometry for sperm DNA integrity) are Not Covered or Reimbursable for the listed indications.

Medically Necessary CFTR and related testing

Considered Medically Necessary when ALL of the following are met:

Medically necessary condition: Criteria in the applicable policy statements listed above are met for CFTR and related testing (e.g., CPTs 81220, 81221, 81222, 81224, 81403, 89329).

The policy excludes a number of broad reproductive screening approaches and expanded prenatal applications. Specifically, a multigene reproductive carrier screening panel with ≥15 genes is Not Covered. Sequencing‑based NIPT is limited to screening for fetal trisomies 13, 18, and 21; sequencing‑based NIPT for other indications (including rare autosomal trisomies, microdeletions, single‑gene disorders, fetal sex determination, higher‑order multiples, vanishing twin, and other expanded uses) is Not Covered or reimbursable only when justification meets policy exceptions. Molecular analysis of intact fetal cells from maternal samples is also not covered.

Large, expanded pan‑ethnic carrier screening panels that lack established gene‑selection criteria are not supported because there is insufficient evidence that they improve health or pregnancy outcomes; these panels are listed as Not Covered. Preimplantation genetic testing (PGT) for nonmedical trait selection (for example, eye or hair color) and applications such as PGT‑P (polygenic risk scoring) are considered experimental/unsupported and are Not Medically Necessary. Use of PGT solely to determine carrier status or to identify donor/recipient matches is not supported.

Genotyping for common MTHFR polymorphisms is explicitly excluded. The policy states that MTHFR polymorphism testing should not be ordered as part of the clinical evaluation for thrombophilia or for recurrent pregnancy loss and is listed as Not Covered (e.g., CPT 81291).

Sperm DNA integrity testing (for example, SCSA, TUNEL, Comet, HSAA/SDD™) is not supported for routine evaluation and management of male‑factor infertility. The policy indicates that the clinical utility of these assays has not been established and such testing is Not Covered or not recommended as part of the initial infertility evaluation.

The policy identifies specific expanded carrier and obstetrics panels and cfDNA single‑gene tests that are listed as Not Covered or not reimbursable, including examples such as the obstetrics expanded carrier screening panel (CPT/HCPCS 0400U), genomic sequence panels of ≥15 genes (e.g., 81443), and single‑gene cfDNA NIPT assays (e.g., 0489U). Whole‑genome U‑codes describing comprehensive genome sequencing in these contexts are likewise listed among excluded services.

Certain specific gene variant tests and broad whole‑genome U‑codes are identified as Not Medically Necessary or Not Covered when used in the reproductive testing contexts described. Examples include reporting of specific thrombophilia‑related variants (e.g., F7 R353Q, F13B V34L) or APOE common variants using molecular pathology Level 1/2 codes (81400/81401) for recurrent pregnancy loss, and whole genome sequencing U‑codes (e.g., 0335U, 0336U) listed as Not Covered.

The policy excludes use of covered procedure codes to report microdeletion testing that the policy designates as not covered or reimbursable. Reporting fetal microdeletion cfDNA analysis using codes identified in the Not Covered list will not be considered medically necessary and may be denied.

The policy explicitly lists several procedure codes and U‑codes as Not Covered or not reimbursable for the specified fetal/reproductive indications. Examples called out include 81422 (fetal chromosomal microdeletion genomic sequence analysis from maternal cfDNA), 0341U (fetal aneuploidy DNA sequencing comparative analysis from products of conception), 81291 (MTHFR common variant testing), and 88182 when used to report sperm DNA integrity testing.

When sperm DNA integrity testing is reported using CPT 88182 (flow cytometry, cell cycle or DNA analysis), the policy states this use is Not Covered or Reimbursable. Claims submitted with this code for sperm DNA integrity testing may be denied.

Operational changes from the 11/01/2024 annual review were applied to the policy. Specifically, prior policy statements for genetic counseling, preimplantation genetic testing for aneuploidy (PGT‑A), and in‑vitro fertilization services associated with preimplantation genetic diagnosis were removed; providers should verify current prior authorization and documentation expectations in light of these deletions.

Reproductive carrier screening offered solely on the basis of general population risk (outside the specific situations and panels identified in the policy, such as the ACMG/ACOG CFTR panel or Ashkenazi Jewish targeted panels) is considered Not Medically Necessary. Targeted and ethnicity‑guided screening approaches meeting the policy criteria remain the supported pathways.

Disallowed or unsupported uses include preimplantation genetic testing for nonmedical selection (for example, gender or cosmetic traits), PGT‑P (polygenic risk scoring), and sequencing‑based NIPT applications for microdeletions, rare autosomal trisomies, or single‑gene disorders when those uses lack clinical validation or professional society support; these applications are Not Medically Necessary or Not Covered per the policy.

The policy specifies that single‑gene mutation analysis is not indicated as part of the routine work‑up for recurrent pregnancy loss due to insufficient evidence of clinical usefulness. Examples of single‑gene tests considered not medically necessary in recurrent pregnancy loss evaluation include F7 (R353Q), F13B (V34L), and PAI‑1 testing.

Reporting certain common variants in the context of recurrent pregnancy loss or general reproductive testing is not supported. Specifically, reporting of F7 (R353Q) and F13B (V34L) variants using molecular pathology Level 1 code(s) and reporting APOE common variants using Level 2 code(s) are identified as Not Medically Necessary for these contexts.

The policy provides a list of multiple gene tests and molecular procedures that are considered Not Medically Necessary when used for the indicated reproductive or recurrent pregnancy loss contexts. These include numerous full‑gene sequencing and molecular pathology levels (examples: APC full sequence, various molecular pathology Level 4–9 procedures, hereditary colon cancer panels such as 81435/81436 when used in unsupported contexts) as enumerated in the coding groups.

Microdeletion testing reporting scenarios that the policy designates as not covered or reimbursable are explicitly excluded. The policy warns that use of codes to report these excluded microdeletion analyses (for example, fetal microdeletion cfDNA testing) will not be considered medically necessary and claims may be denied.

The policy highlights specific procedure codes that are considered Not Medically Necessary or not covered when used for reproductive testing contexts. For example, CPT 81229 (cytogenomic genome‑wide microarray) is considered not medically necessary when used to report reproductive genetic testing for recurrent pregnancy loss or for preimplantation genetic screening for common aneuploidy. Likewise, molecular pathology Level 1 code 81400 is identified as not medically necessary for particular recurrent pregnancy loss single‑gene tests.

Covered Indications

Not Covered / Not Medically Necessary

A consolidated restatement of the Not Covered list reiterates that sequencing‑based NIPT for indications beyond trisomy 13/18/21 (including rare trisomies, microdeletions, and single‑gene disorders) and large expanded pan‑ethnic carrier panels without established gene‑selection criteria are Not Covered. MTHFR genotyping and sperm DNA integrity testing are also explicitly listed as not covered or reimbursable in the Not Covered section.

The policy states that large expanded pan‑ethnic carrier panels lacking established inclusion criteria are Not Covered. It also specifies that PGT for nonmedical traits, PGT‑P (polygenic risk scoring), and PGT used solely for donor/recipient matching or nonmedical indication are not supported and therefore Not Covered or Not Medically Necessary.

MTHFR common variant testing (e.g., CPT 81291) is explicitly listed as Not Covered for evaluation of thrombophilia or recurrent pregnancy loss. Whole genome sequencing U‑codes (0335U, 0336U) are also listed among services not covered in these reproductive contexts.

The policy reaffirms that routine cfDNA screening for microdeletions is not recommended given limited validation data and low positive predictive value; sequencing‑based NIPT for these expanded targets is Not Covered owing to unclear clinical utility.

Single‑gene tests that have been proposed for recurrent pregnancy loss (for example, F7 R353Q, F13B V34L, and PAI‑1) lack evidence that testing improves clinical outcomes and are considered Not Medically Necessary in the routine recurrent pregnancy loss work‑up.

The policy explicitly lists certain expanded carrier and genomic sequence panels and single‑gene cfDNA tests as Not Covered: examples include 0400U (obstetrics expanded carrier screening), genomic sequence panels such as 81443, single‑gene cfDNA NIPT codes like 0489U, and reporting of specific common variants in unsupported contexts.

Coding and Billing Guidance

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required for NIPT

Sequencing-based NIPT (trisomy 13/18/21) may require prior authorization. Providers should obtain prior authorization when applicable and verify in-network laboratory requirements prior to ordering. In-network coverage of sequencing-based NIPT performed out-of-network is considered not medically necessary and may be denied.

Applicable CPTs: 81420, 81507, 0327U
Ensure testing is for viable singleton or twin gestation ≥10 weeks when requesting authorization
If ordered for indications outside covered purposes (e.g., microdeletions, rare autosomal trisomies, single-gene disorders, higher-order multiples), expect denial

Prior Authorization

NIPS Requires Diagnostic Confirmation

Positive NIPS/cfDNA screening results are screening only and require confirmatory invasive diagnostic testing (CVS or amniocentesis) for diagnosis and clinical decision-making. Prior authorization may be required for both the screening and for confirmatory diagnostic testing depending on the member's plan and indications.

Document counseling offered about need for diagnostic confirmation when reporting a positive NIPS result

Definitions

Germline genetic testing definition

DefinitionAnalysis of germline DNA/RNA/chromosomes to detect inherited variants passed via blood relatives

Use casesUsed for reproductive carrier screening, prenatal diagnosis, recurrent pregnancy loss and infertility evaluation

Clinical purposeDetects heritable variants to inform reproductive planning and risk to offspring

Preimplantation genetic testing (PGT) definition

DefinitionBiopsy of embryo to obtain cells for genetic testing (PGT-M for monogenic disorders; PGT-SR for structural rearrangements)

Coverage conditionCovered when condition is severe/lethal, test impacts clinical decision-making, and parental carrier/translocation criteria met

Eligibility Requirements

Eligibility for coverage of carrier screening and preimplantation testing is generally contingent on a demonstrated family history or parental carrier status. For example, targeted testing for CFTR, SMN1, or hemoglobinopathy genes is considered medically necessary when a prospective biologic parent with the capacity and intention to reproduce has not previously been tested and when family history or ancestry (e.g., Ashkenazi Jewish descent) indicates elevated risk.

Carrier screening and PGT indications generally require documentation of a known family history or parental carrier status. The policy emphasizes targeted and stepwise approaches (for example, targeted mutation analysis per ACMG for CFTR followed by sequencing if indicated) rather than routine use of very large expanded panels without established inclusion criteria.

Additional eligibility details include that many single‑gene carrier tests are considered medically necessary when testing has not previously been performed and results will impact reproductive decision‑making; for recurrent pregnancy loss, cytogenetic testing of parents and products of conception is supported in appropriate clinical scenarios.

For thalassemia and sickle cell disease, the policy supports a stepwise testing strategy: targeted mutation analysis (HBB, HBA1, HBA2) is first‑line, with sequencing and deletion/duplication studies reserved for follow‑up when indicated or when targeted testing is negative.

Background

Background: Germline variants are inherited changes in DNA that can be transmitted to offspring. Reproductive carrier screening, preimplantation testing, and prenatal diagnostic testing are performed to detect such variants and inform reproductive planning and management. Professional society guidance (ACMG, ACOG) supports targeted carrier testing and use of sequencing‑based NIPT for detection of common autosomal trisomies when policy criteria are met.

Revision History

2025-10-15policy_reviewLatest

Policy last reviewed on 2025-10-15 per document metadata (last_review).

2024-11-01annual_review

Annual review updated and revised policy language for germline carrier testing, Fragile X, Ashkenazi Jewish descent testing, preimplantation genetic testing, and fetal testing; removed prior policy statements for genetic counseling, preimplantation genetic testing for aneuploidy, and IVF services associated with preimplantation genetic diagnosis.

2023-12-15

OpenPayer

Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

Coverage Criteria

Covered Indications

Not Covered / Not Medically Necessary

Coding and Billing Guidance

Provider Actions & Authorization

Definitions

Eligibility Requirements

Background

Revision History